Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06138691 · ClinicalTrials.gov registry record · Phase 1
KET-RO Plus RO DBT for Treatment Resistant Depression
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT06138691 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 16 participants.
The verdict
NCT06138691, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This pilot study will assess the safety and feasibility of intravenous (IV) ketamine combined with RO DBT in young adults with Treatment-Resistant Depression (TRD). In addition, this study will develop and utilize innovative methodological approaches to demonstrate the feasibility of precision medicine with this type of therapy.
Interventions
- COMBINATION_PRODUCT Ketamine Infusion plus RO DBT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-10-04 |
| Est. Completion | 2025-02-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06138691
The ClinicalTrials.gov registry entry for NCT06138691 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ketamine Infusion plus RO DBT is the first listed.
NCT06138691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06138691 about?
NCT06138691 is a clinical study titled "KET-RO Plus RO DBT for Treatment Resistant Depression". This pilot study will assess the safety and feasibility of intravenous (IV) ketamine combined with RO DBT in young adults with Treatment-Resistant Depression (TRD). In addition, this study will develop and utilize innovative methodological approaches to demonstrate the feasibility of precision medic...
What is the current status of trial NCT06138691?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-10-04. Estimated completion is 2025-02-22.
What interventions are being tested in trial NCT06138691?
The interventions under investigation include: Ketamine Infusion plus RO DBT (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06138691?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.